Progress reportProton pump inhibitors - differences emerge in hepatic metabolism
References (45)
- et al.
A PPI is a PPI is a PPI; lessons from prolonged intragastric pH monitoring
Gastroenterology
(2000) Effect of genetic differences in lansoprazole metabolism on intragastric pH
Gastroenterology
(2001)Effect of genotypic differences in CYP2C 19 status on the cure rate for gastroesophageal reflux disease by lansoprazole
Gastroenterology
(2001)Proton pump inhibitors and acid-related diseases
Pharmacotherapy
(1997)- et al.
Effect of omeprazole - a gastric proton pump inhibitor on pentagastrin stimulated acid secretion in man
Gut
(1983) - et al.
Interaction of human liver cytochromes P450 in vitro with LY307640, a gastric proton pump inhibitor
Pharmacogenetics
(1996) - et al.
Comparison of the kinetic disposition and metabolism of E3810, a new proton pump inhibitor, and omeprazole in relation to S-mephenytoin 4′-hydroxylation status
Clin Pharmacol Ther
(1995) - et al.
Identification of human liver cytochrome P450 isoforms mediating secondary omeprazole metabolism
Br J Clin Pharmacol
(1994) The interaction of proton pump inhibitors with cytochromes P450
Aliment Pharmacol Ther
(1994)- et al.
Steroselective metabolism of omeprazole by human cytochrome P450 enzymes
Drug Metabolism and Disposition
(2000)
Metabolic interactions of the proton-pump inhibitors lansoprazole, omeprazole and pantoprazole with other drugs
Eur J Gastroenterol Hepatol
Oxidative metabolism of omeprazole in human liver microsomes: cosegregation with S-mephenytoin 4′-hydroxylation
J Pharmacol Exp Ther
Pharmacokinetics, metabolism and interactions of acid pump inhibitors. Focus on omeprazole, lansoprazole and pantoprazole
Clin Pharmacokinet
Review article: cytochrome P450 and the metabolism of proton pump inhibitors - emphasis on rabeprazole
Aliment Pharmacol Therapeutics
Genetic polymorphism of S-mephenytoin 4′-hydroxylation in African-Americans
Pharmacogenetics
Pharmacogenetics of mephenytoin: a new drug hydroxylation polymorphism in man
Eur J Clin Pharmacol
S-mephenytoin hydroxylation phenotypes in a Swedish population determined after co-administration with debrisoquin
Clin Pharmacol Ther
Phenotyping polymorphic drug metabolism in the French Caucasian population
Eur J Clin Pharmacol
Mephenytoin hydroxylation deficiency in Caucasians: frequency of a new oxidative drug metabolism polymorphism
Clin Pharmacol Ther
Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S-mephenytoin
Clin Pharmacol Ther
Incidence of S-mephenytoin hydroxylation deficiency in a Korean population and the interphenotypic differences in diazepam pharmacokinetics
Clin Pharmacol Ther
Metoprolol and mephenytoin oxidation polymorphisms in Far Eastern Oriental subjects: Japanese versus mainland Chinese
Clin Pharmacol Ther
Cited by (74)
Updates in Telemedicine for Gastroenterology Practices in the United States
2022, Clinical Gastroenterology and HepatologyAppropriateness of proton pump inhibitors treatment in clinical practice: Prospective evaluation in outpatients and perspective assessment of drug optimisation
2020, Digestive and Liver DiseaseCitation Excerpt :This latter finding needs to be emphasised as it may represent a source of unexpected and potentially dangerous modifications in International Normalised Ratio values due to the alterations in gastric absorption of anti-coagulants or to the occurrence of drug-drug interactions via hepatic cytochrome P-450 metabolism. These speculations are also reflected by the finding that pantoprazole, which together with rabeprazole lacks significant inhibition of CYP2C19, was the most frequently prescribed PPI [42–45]. The strengths of our study are its prospective design, the large sample of patients referred to our outpatients clinic, the assessment of the appropriate reasons for PPI prescription with the accurate recording of dose, modalities of drug administration and duration of treatment, the attention for prescriber speciality and, more importantly, the modifications of PPI prescription following specialist counselling on the basis of the current step-down regimen recommendations [19–22].
The Impact of Sex on the Response to Proton Pump Inhibitor Treatment
2023, Pharmaceuticals